JP2015500241A - 両親媒性脂質をベースとする徐放性組成物 - Google Patents

両親媒性脂質をベースとする徐放性組成物 Download PDF

Info

Publication number
JP2015500241A
JP2015500241A JP2014544937A JP2014544937A JP2015500241A JP 2015500241 A JP2015500241 A JP 2015500241A JP 2014544937 A JP2014544937 A JP 2014544937A JP 2014544937 A JP2014544937 A JP 2014544937A JP 2015500241 A JP2015500241 A JP 2015500241A
Authority
JP
Japan
Prior art keywords
composition
active ingredient
sustained release
hours
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014544937A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500241A5 (https=
Inventor
スコット エイ． ハワード
スコット エイ． ハワード
トロイ パービス
トロイ パービス
Original Assignee
ペガサス ラボラトリーズ インコーポレイテッド
ペガサス ラボラトリーズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ペガサス ラボラトリーズ インコーポレイテッド, ペガサス ラボラトリーズ インコーポレイテッド filed Critical ペガサス ラボラトリーズ インコーポレイテッド
Publication of JP2015500241A publication Critical patent/JP2015500241A/ja
Publication of JP2015500241A5 publication Critical patent/JP2015500241A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014544937A 2011-12-02 2012-11-30 両親媒性脂質をベースとする徐放性組成物 Pending JP2015500241A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161566279P 2011-12-02 2011-12-02
US61/566,279 2011-12-02
PCT/US2012/067361 WO2013082470A1 (en) 2011-12-02 2012-11-30 Amphipathic lipid-based sustained release compositions

Publications (2)

Publication Number Publication Date
JP2015500241A true JP2015500241A (ja) 2015-01-05
JP2015500241A5 JP2015500241A5 (https=) 2017-01-26

Family

ID=48524178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014544937A Pending JP2015500241A (ja) 2011-12-02 2012-11-30 両親媒性脂質をベースとする徐放性組成物

Country Status (8)

Country Link
US (1) US9248096B2 (https=)
EP (1) EP2785333A4 (https=)
JP (1) JP2015500241A (https=)
AU (1) AU2012345726B2 (https=)
BR (1) BR112014013175B1 (https=)
CA (1) CA2854054C (https=)
MX (1) MX351453B (https=)
WO (1) WO2013082470A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012019168A2 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2625189B1 (en) 2010-10-01 2018-06-27 ModernaTX, Inc. Engineered nucleic acids and methods of use thereof
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DE19216461T1 (de) 2011-10-03 2021-10-07 Modernatx, Inc. Modifizierte nukleoside, nukleotide und nukleinsäuren und verwendungen davon
CA3018046A1 (en) 2011-12-16 2013-06-20 Moderna Therapeutics, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013151665A2 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins associated with human disease
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
PL2922554T3 (pl) 2012-11-26 2022-06-20 Modernatx, Inc. Na zmodyfikowany na końcach
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
WO2017048859A1 (en) * 2015-09-16 2017-03-23 Corr-Jensen, Inc. Multi-phase release of sports nutrition and energy drink compositions utilizing lipid particulates
JP6948313B6 (ja) 2015-09-17 2022-01-14 モデルナティエックス インコーポレイテッド 治療剤の細胞内送達のための化合物および組成物
PL3386484T3 (pl) 2015-12-10 2022-07-25 Modernatx, Inc. Kompozycje i sposoby dostarczania środków terapeutycznych
LT3394030T (lt) 2015-12-22 2022-04-11 Modernatx, Inc. Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu
US11583504B2 (en) 2016-11-08 2023-02-21 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
EP4186888B1 (en) 2017-03-15 2025-11-26 ModernaTX, Inc. Compound and compositions for intracellular delivery of therapeutic agents
CA3055653A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Lipid nanoparticle formulation
WO2018170322A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Crystal forms of amino lipids
WO2018232120A1 (en) 2017-06-14 2018-12-20 Modernatx, Inc. Compounds and compositions for intracellular delivery of agents
US20190110988A1 (en) * 2017-10-17 2019-04-18 Lemulsa Technologies Inc. Delivery System That Utilizes Liposomal or Emulsion Vehicles
CA3113025A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Peg lipids and uses thereof
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
WO2020061367A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. Compounds and compositions for intracellular delivery of therapeutic agents
EP3886814B1 (en) 2018-11-26 2025-02-19 The Procter & Gamble Company Solid pharmaceutical preparation containing lipoic acid and use thereof
AU2020350759A1 (en) 2019-09-19 2022-03-31 Modernatx, Inc. Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
CA3155015A1 (en) 2019-09-19 2021-03-25 Modernatx, Inc. Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents
US11524023B2 (en) 2021-02-19 2022-12-13 Modernatx, Inc. Lipid nanoparticle compositions and methods of formulating the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US6197314B1 (en) * 1997-09-18 2001-03-06 Warner Lambert Company Impeding the extraction of active ingredients out of tablets
JP2003501457A (ja) * 1999-06-14 2003-01-14 コスモ ソシエタ ペル アチオニ 制御放出および味感遮蔽経口医薬組成物
WO2010028290A1 (en) * 2008-09-04 2010-03-11 Farnam Companies, Inc. Chewable sustained release formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993850A (en) * 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6077534A (en) * 1997-09-02 2000-06-20 Klinge Pharma Gmbh Production of pharmaceutical formulations for treatment of edema and venous disorders
ES2331442T3 (es) 1998-03-23 2010-01-04 General Mills, Inc. Encapsulacion de componentes en productos comestibles.
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
PL204079B1 (pl) * 2004-08-12 2009-12-31 Inst Farmaceutyczny Stały doustny preparat chlorowodorku tamsulozyny o przedłużonym uwalnianiu i sposób jego wytwarzania
ATE476176T1 (de) 2007-03-02 2010-08-15 Farnam Co Inc Wachsähnliches material enthaltende tabletten mit verzögerter freisetzung
US8404275B2 (en) 2007-07-01 2013-03-26 Vitalis Llc Combination tablet with chewable outer layer
WO2010136193A1 (en) * 2009-05-28 2010-12-02 Krka, Tovarna Zdravil, D.D., Novo Mesto Pharmaceutical composition comprising tamsulosin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6348226A (ja) * 1986-08-14 1988-02-29 Ono Pharmaceut Co Ltd 徐放性を有する経口投与用固形製剤
US6197314B1 (en) * 1997-09-18 2001-03-06 Warner Lambert Company Impeding the extraction of active ingredients out of tablets
JP2003501457A (ja) * 1999-06-14 2003-01-14 コスモ ソシエタ ペル アチオニ 制御放出および味感遮蔽経口医薬組成物
WO2010028290A1 (en) * 2008-09-04 2010-03-11 Farnam Companies, Inc. Chewable sustained release formulations

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
化学大辞典９（縮刷版）, JPN6017004974, 1987, pages 885 - 886, ISSN: 0003500757 *

Also Published As

Publication number Publication date
EP2785333A1 (en) 2014-10-08
BR112014013175B1 (pt) 2022-08-09
US20130142876A1 (en) 2013-06-06
AU2012345726B2 (en) 2017-04-13
CA2854054A1 (en) 2013-06-06
EP2785333A4 (en) 2015-04-01
NZ624641A (en) 2016-04-29
US9248096B2 (en) 2016-02-02
AU2012345726A1 (en) 2014-05-29
MX351453B (es) 2017-10-16
BR112014013175A8 (pt) 2021-06-08
WO2013082470A1 (en) 2013-06-06
MX2014006271A (es) 2014-09-22
BR112014013175A2 (pt) 2017-06-13
CA2854054C (en) 2020-05-12

Similar Documents

Publication Publication Date Title
CA2854054C (en) Amphipathic lipid-based sustained release compositions
JP5608653B2 (ja) チュアブルな徐放性製剤
US20210113469A1 (en) Sustained release compositions using wax-like materials
WO2007052299A2 (en) Controlled release formulation
US10722458B2 (en) Amphipathic lipid-based sustained release compositions
NZ624641B2 (en) Amphipathic lipid-based sustained release compositions
HK1141441B (en) Sustained release pellets comprising wax-like material
WO2017078557A1 (ru) Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой аналога

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20161130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170817

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170912